P53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines

Cancer Chemotherapy and Pharmacology

Volumn 77, Issue 2, 2016, Pages 349-356

  Ye, Shunan ^a,b   Shen, Jacson ^a   Choy, Edwin ^a   Yang, Cao ^b   Mankin, Henry ^a   Hornicek, Francis ^a   Duan, Zhenfeng ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; MDR; Osteosarcoma; p53

Indexed keywords

CISPLATIN; DOXORUBICIN; LIPOFECTAMINE; PACLITAXEL; PROTEIN BAX; PROTEIN P21; PROTEIN P53; SOMATOMEDIN C RECEPTOR; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1A; IGF1R PROTEIN, HUMAN; SOMATOMEDIN RECEPTOR;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CHEMOSENSITIVITY; DOWN REGULATION; DRUG CYTOTOXICITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; BONE NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MUTATION; PHARMACOGENETICS; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BONE NEOPLASMS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENES, P53; HUMANS; MUTATION; OSTEOSARCOMA; PHARMACOGENETICS; RECEPTORS, SOMATOMEDIN;

EID: 84958039284     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2944-z     Document Type: Article

References (55)

1. Chou AJ, Gorlick R (2006) Chemotherapy resistance in osteosarcoma: current challenges and future directions. Exp Rev Anticancer Ther 6(7):1075-1085. doi: 10.1586/14737140.6.7.1075
2. Chou AJ, Merola PR, Wexler LH, Gorlick RG, Vyas YM, Healey JH, LaQuaglia MP, Huvos AG, Meyers PA (2005) Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 104(10):2214-2221. doi: 10.1002/cncr.21417
3. Hawkins DS, Arndt CA (2003) Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 98(11):2447-2456. doi: 10.1002/cncr.11799
4. Kartner N, Riordan JR, Ling V (1983) Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221(4617):1285-1288
5. Perez-Tomas R (2006) Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 13(16):1859-1876
6. Ross DD (2000) Novel mechanisms of drug resistance in leukemia. Leukemia 14(3):467-473
7. Guo Y, Xu F, Lu T, Duan Z, Zhang Z (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38(7):904-910. doi: 10.1016/j.ctrv.2012.04.007
8. Susa M, Milane L, Amiji MM, Hornicek FJ, Duan Z (2011) Nanoparticles: a promising modality in the treatment of sarcomas. Pharm Res 28(2):260-272. doi: 10.1007/s11095-010-0173-z
9. Duffy MJ, Synnott NC, McGowan PM, Crown J, O'Connor D, Gallagher WM (2014) p53 as a target for the treatment of cancer. Cancer Treat Rev 40(10):1153-1160. doi: 10.1016/j.ctrv.2014.10.004
10. Ozaki T, Nakagawara A (2011) p53: the attractive tumor suppressor in the cancer research field. J Biomed Biotechnol 2011:603925. doi: 10.1155/2011/603925
11. Feng Z, Zhang H, Levine AJ, Jin S (2005) The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 102(23):8204-8209. doi: 10.1073/pnas.0502857102
12. Selvarajah J, Nathawat K, Moumen A, Ashcroft M, Carroll VA (2013) Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways. Cell Death Dis 4:e865. doi: 10.1038/cddis.2013.395
13. Lourda M, Trougakos IP, Gonos ES (2007) Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of clusterin/apolipoprotein. J Int J Cancer 120(3):611-622. doi: 10.1002/ijc.22327
14. Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, Mankin H, Hornicek FJ (2009) Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther 8(8):2122-2130. doi: 10.1158/1535-7163.MCT-09-0115
15. Boyd SD, Tsai KY, Jacks T (2000) An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat Cell Biol 2(9):563-568. doi: 10.1038/35023500
16. Castro ME, Leal JF, Lleonart ME, Ramon YCS, Carnero A (2008) Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 function. Carcinogenesis 29(7):1343-1350. doi: 10.1093/carcin/bgm302
17. Mossalam M, Matissek KJ, Okal A, Constance JE, Lim CS (2012) Direct induction of apoptosis using an optimal mitochondrially targeted p53. Mol Pharm 9(5):1449-1458. doi: 10.1021/mp3000259
18. Han L, Zhao J, Liu J, Duan XL, Li LH, Wei XF, Wei Y, Liang XJ (2014) A universal gene carrier platform for treatment of human prostatic carcinoma by p53 transfection. Biomaterials 35(9):3110-3120. doi: 10.1016/j.biomaterials.2013.12.048
19. Duan Z, Li X, Huang H, Yuan W, Zheng SL, Liu X, Zhang Z, Choy E, Harmon D, Mankin H, Hornicek F (2012) Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer. J Med Chem 55(7):3113-3121. doi: 10.1021/jm300117u
20. David-Pfeuty T, Chakrani F, Ory K, Nouvian-Dooghe Y (1996) Cell cycle-dependent regulation of nuclear p53 traffic occurs in one subclass of human tumor cells and in untransformed cells. Cell Growth Differ 7(9):1211-1225
21. Ganjavi H, Gee M, Narendran A, Parkinson N, Krishnamoorthy M, Freedman MH, Malkin D (2006) Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther 13(4):415-419. doi: 10.1038/sj.cgt.7700909
22. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV (2003) Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3(1):1-19
23. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3):219-234. doi: 10.1038/nrd1984
24. Tognon CE, Sorensen PH (2012) Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy. Exp Opin Ther Targets 16(1):33-48. doi: 10.1517/14728222.2011.638626
25. Pan Y, Trojan J, Guo Y, Anthony DD (2013) Rescue of MHC-1 antigen processing machinery by down-regulation in expression of IGF-1 in human glioblastoma cells. PLoS ONE 8(3):e58428. doi: 10.1371/journal.pone.0058428
26. Davison Z, de Blacquiere GE, Westley BR, May FE (2011) Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia 13(6):504-515
27. Li R, Pourpak A, Morris SW (2009) Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem 52(16):4981-5004. doi: 10.1021/jm9002395
28. Baxter RC (2014) IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer 14(5):329-341. doi: 10.1038/nrc3720
29. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8(12):915-928. doi: 10.1038/nrc2536
30. Ho L, Stojanovski A, Whetstone H, Wei QX, Mau E, Wunder JS, Alman B (2009) Gli2 and p53 cooperate to regulate IGFBP-3- mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. Cancer Cell 16(2):126-136. doi: 10.1016/j.ccr.2009.05.013
31. Shen L, Dean NM, Glazer RI (1999) Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase Calpha antisense oligonucleotide. Mol Pharmacol 55(2):396-402
32. Gimenez-Bonafe P, Tortosa A, Perez-Tomas R (2009) Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets 9(3):320-340
33. Ketley NJ, Allen PD, Kelsey SM, Newland AC (2000) Mechanisms of resistance to apoptosis in human AML blasts: the role of differentiation-induced perturbations of cell-cycle checkpoints. Leukemia 14(4):620-628
34. Le Bras M, Rouy I, Brenner C (2006) The modulation of inter-organelle cross-talk to control apoptosis. Med Chem 2(1):1-12
35. Roos WP, Kaina B (2006) DNA damage-induced cell death by apoptosis. Trends Mol Med 12(9):440-450. doi: 10.1016/j.molmed.2006.07.007
36. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31(15):1869-1883. doi: 10.1038/onc.2011.384
37. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4(4):307-320. doi: 10.1038/nrd1691
38. Miao ZH, Tong LJ, Zhang JS, Han JX, Ding J (2004) Characterization of salvicine-resistant lung adenocarcinoma A549/SAL cell line. Int J Cancer 110(5):627-632. doi: 10.1002/ijc.20026
39. Mayer F, Stoop H, Scheffer GL, Scheper R, Oosterhuis JW, Looijenga LH, Bokemeyer C (2003) Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res 9(2):767-773
40. Kim CW, Lu JN, Go SI, Jung JH, Yi SM, Jeong JH, Hah YS, Han MS, Park JW, Lee WS, Min YJ (2013) p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax. Int J Oncol 43(5):1495-1502. doi: 10.3892/ijo.2013.2070
41. Cho HJ, Kim JK, Kim KD, Yoon HK, Cho MY, Park YP, Jeon JH, Lee ES, Byun SS, Lim HM, Song EY, Lim JS, Yoon DY, Lee HG, Choe YK (2006) Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett 237(1):56-66. doi: 10.1016/j.canlet.2005.05.039
42. Sugimoto C, Fujieda S, Seki M, Sunaga H, Fan GK, Tsuzuki H, Borner C, Saito H, Matsukawa S (1999) Apoptosis-promoting gene (bax) transfer potentiates sensitivity of squamous cell carcinoma to cisplatin in vitro and in vivo. Int J Cancer 82(6):860-867
43. Gartel AL, Radhakrishnan SK (2005) Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65(10):3980-3985. doi: 10.1158/0008-5472.CAN-04-3995
44. Mirzayans R, Andrais B, Scott A, Wang YW, Murray D (2013) Ionizing radiation-induced responses in human cells with differing TP53 status. Int J Mol Sci 14(11):22409-22435. doi: 10.3390/ijms141122409
45. Liu S, Bishop WR, Liu M (2003) Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. Drug Res Updates 6(4):183-195
46. Waga S, Hannon GJ, Beach D, Stillman B (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369(6481):574-578. doi: 10.1038/369574a0
47. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75(4):805-816
48. Niculescu AB 3rd, Chen X, Smeets M, Hengst L, Prives C, Reed SI (1998) Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 18(1):629-643
49. Ogryzko VV, Wong P, Howard BH (1997) WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol 17(8):4877-4882
50. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119(6):861-872. doi: 10.1016/j.cell.2004.11.006
51. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119(6):847-860. doi: 10.1016/j.cell.2004.11.004
52. Linn SC, Honkoop AH, Hoekman K, van der Valk P, Pinedo HM, Giaccone G (1996) p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 74(1):63-68
53. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, Wang Q, Zambetti GP, Schuetz JD (2001) Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276(42):39359-39367. doi: 10.1074/jbc.M103429200
54. Vasey PA, Jones NA, Jenkins S, Dive C, Brown R (1996) Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol 50(6):1536-1540
55. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A (2006) Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 25(2):304-309. doi: 10.1038/sj.onc.1209026